Enhanced expression of anti-apoptotic B-cell lymphoma 2 (BCL-2) protein is frequent in
cancer. Targeting of BCL-2 with the specific inhibitor ABT-199 (Venetoclax) has significant …

Mutations that impair apoptosis contribute to cancer development and reduce the
effectiveness of conventional anti-cancer therapies. These insights and understanding of …

With the advent of new agents targeting CD20, Bruton's tyrosine kinase, and
phosphoinositol-3 kinase for chronic lymphoid leukemia (CLL), more treatment options exist …

Several cancer cell types, including chronic lymphocytic leukemia (CLL) and diffuse large B-
cell lymphoma (DLBCL) upregulate antiapoptotic Bcl-2 to cope with oncogenic stress. BH3 …

Navitoclax is a selective small-molecule B-cell lymphoma 2 (BCL-2)/BCL-XL inhibitor that
represents both the fruition of nearly three decades of BCL-2 protein research and the …

The intracellular protein B‐cell‐lymphoma‐2 (BCL2) has been considered an attractive
target for cancer therapy since the discovery of its function as a major promoter of cell …

Abstract The BH3-mimetic ABT-737 and an orally bioavailable compound of the same class,
navitoclax (ABT-263), have shown promising antitumor efficacy in preclinical and early …

Simple Summary Apoptosis, a programmed form of cell death, represents the main
mechanism by which cells die. Such phenomenon is highly regulated by the BCL-2 family of …

Improving outcomes in acute myeloid leukemia (AML) remains a major clinical challenge.
Overexpression of pro-survival BCL-2 family members rendering transformed cells resistant …

Targeting BCL-2, a key regulator of survival in B-cell malignancies including precursor B-cell
acute lymphoblastic leukemia, has become a promising treatment strategy. However, given …